Key terms
About XRTX
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XRTX news
Apr 22
8:19am ET
XORTX’s Breakthrough Study on Kidney Disease
Apr 22
7:57am ET
XORTX’s Research Offers New Hope for ADPKD
Apr 22
7:21am ET
Xortx Therapeutics announces publication on research of ADPKD
Apr 08
8:08am ET
XORTX Therapeutics Boosts Board with Biotech Pro
Apr 08
7:59am ET
XORTX Gears Up for Spring 2024 Investor Conferences
Apr 08
7:57am ET
XORTX Therapeutics Appoints Industry Leader to Board
Apr 08
7:48am ET
XORTX Therapeutics Engages Investors in Spring Events
Apr 08
7:31am ET
Xortx Therapeutics appoints Abigail Jenkins to board of directors
Apr 04
6:57am ET
Xortx Therapeutics Reports Stable Finances
Mar 20
6:58am ET
XORTX Gears Up for Kidney Disease Trial Advancements
Mar 19
6:37am ET
XORTX Therapeutics Advances Kidney Disease Program
Mar 11
7:39am ET
XORTX Therapeutics Announces Warrant Repricing
Mar 07
9:53am ET
Xyratex Ltd. trading resumes
Mar 07
9:48am ET
Xyratex Ltd. trading halted, volatility trading pause
No recent press releases are available for XRTX
XRTX Financials
Key terms
Ad Feedback
XRTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XRTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range